Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Pegram

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Frontiers in Genetics|February 22, 2021
RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology StrategiesAnja van de Stolpe, Wim Verhaegh, Jean-Yves Blay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2011
Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancerNuhad K Ibrahim, Kemal O Yariz, Ihor Bondarenko, et al.
Clinical Breast Cancer|February 5, 2020
Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG)Muaiad Kittaneh, Sunil Badve, Humberto Caldera, et al.
Clinical Breast Cancer|December 31, 2005
Reducing the global breast cancer burden: the importance of patterns of care researchKathy S Albain, Jaime de la Garza Salazar, Tadeusz Pienkowski, et al.
Journal of the National Cancer Institute|January 17, 2003
Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancerGottfried Konecny, Giovanni Pauletti, Mark Pegram, et al.
Cancer Research|May 20, 2016
Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular DomainKeith L Knutson, Raphael Clynes, Barath Shreeder, et al.
Cancer|June 17, 2014
Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancerPeter A Kaufman, Kenneth J Bloom, Howard Burris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancerStephen Johnston, John Pippen, Xavier Pivot, et al.
Breast Cancer Research : BCR|June 15, 2018
Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancerNadine Norton, Nicholas Fox, Christie-Ann McCarl, et al.
Breast Cancer Research and Treatment|April 27, 2012
Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressorElizabeth Iorns, Toby M Ward, Sonja Dean, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Frontiers in Genetics|February 22, 2021
RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology StrategiesAnja van de Stolpe, Wim Verhaegh, Jean-Yves Blay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2011
Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancerNuhad K Ibrahim, Kemal O Yariz, Ihor Bondarenko, et al.
Clinical Breast Cancer|February 5, 2020
Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG)Muaiad Kittaneh, Sunil Badve, Humberto Caldera, et al.
Clinical Breast Cancer|December 31, 2005
Reducing the global breast cancer burden: the importance of patterns of care researchKathy S Albain, Jaime de la Garza Salazar, Tadeusz Pienkowski, et al.
Journal of the National Cancer Institute|January 17, 2003
Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancerGottfried Konecny, Giovanni Pauletti, Mark Pegram, et al.
Cancer Research|May 20, 2016
Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular DomainKeith L Knutson, Raphael Clynes, Barath Shreeder, et al.
Cancer|June 17, 2014
Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancerPeter A Kaufman, Kenneth J Bloom, Howard Burris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancerStephen Johnston, John Pippen, Xavier Pivot, et al.
Breast Cancer Research : BCR|June 15, 2018
Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancerNadine Norton, Nicholas Fox, Christie-Ann McCarl, et al.
Breast Cancer Research and Treatment|April 27, 2012
Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressorElizabeth Iorns, Toby M Ward, Sonja Dean, et al.
Pageof 7